Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil once-daily for benign prostatic hyperplasia (Phase 3)
2009-010739-42Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Tadalafil 5 mg once daily with Placebo (2 arms). Primary endpoint: Change in IPSS from baseline after 12 weeks. Started Jun 2009; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2009-010739-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010739-42.